Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.47 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.47 |
| ▸ | MAOA | P21397 | 1/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.47 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.47 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.47 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.47 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.44 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.40 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.40 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.40 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2846535 | 1.00 | SIGMAR1 (0.47) | SIGMAR1TAAR1SLC6A2MAOASLC6A4 | |
| SCHEMBL9543263 | 0.87 | SIGMAR1 (0.48) | SIGMAR1TAAR1SLC6A2MAOASLC6A4 | |
| SCHEMBL1047441 | 0.87 | SIGMAR1 (0.48) | SIGMAR1TAAR1SLC6A2MAOASLC6A4 | |
| SCHEMBL8000326 | 0.85 | CSNK1E (0.58) | SIGMAR1TAAR1SLC6A2MAOASLC6A4 | |
| Hydrochloric Acid SCHEMBL9456845 | 0.84 | CSNK1E (0.56) | SIGMAR1TAAR1SLC6A2MAOASLC6A4 | |
| SCHEMBL15562967 | 0.83 | SIGMAR1 (0.49) | SIGMAR1TAAR1SLC6A2MAOASLC6A4 | |
| SCHEMBL4588322 | 0.83 | TAAR1 (0.50) | SIGMAR1TAAR1SLC6A2MAOASLC6A4 | |
| SCHEMBL2604897 | 0.83 | TAAR1 (0.50) | SIGMAR1TAAR1SLC6A2MAOASLC6A4 | |
| SCHEMBL11517810 | 0.83 | EPHX1 (0.48) | SIGMAR1TAAR1SLC6A2MAOASLC6A4 | |
| SCHEMBL7973781 | 0.83 | HTR2A (0.46) | SIGMAR1TAAR1SLC6A2MAOASLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260007672-A1 | INHIBITORS OF MPTP | NRG THERAPEUTICS LTD (GB) | 2026-01-08 | — | — | US | disclosed |
| US-12491185-B2 | Inhibitors of mPTP | NRG THERAPEUTICS LTD (GB) | 2025-12-09 | — | — | US | disclosed |
| EP-4652162-A1 | INHIBITORS OF MPTP | NRG Therapeutics LTD (GB) | 2025-11-26 | — | — | EP | disclosed |
| US-20250177397-A1 | INHIBITORS OF MPTP | NRG THERAPEUTICS LTD (GB) | 2025-06-05 | — | — | US | disclosed |
| WO-2024153946-A1 | INHIBITORS OF MPTP | NRG THERAPEUTICS LTD (GB) | 2024-07-25 | — | — | WO | disclosed |
| WO-2018102885-A1 | MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS AND USES THEREOF | BIONOMICS LIMITED (AU) | 2018-06-14 | — | — | WO | disclosed |
| EP-0424965-A1 | Amine oxide process | ETHYL CORPORATION (US) | 1991-05-02 | — | — | EP | disclosed |
| US-4960934-A | Amine oxide process | ETHYL CORPORATION (US) | 1990-10-02 | — | — | US | disclosed |
| US-4942260-A | REACTION OF A TERT-AMINE WITH HYDROGEN PEROXIDE IN THE PRESENCE OF CATALYTIC CARBON DIOXIDE | ETHYL CORPORATION (US) | 1990-07-17 | — | — | US | disclosed |
| EP-0356918-A1 | Amine oxide process | ETHYL CORPORATION (US) | 1990-03-07 | — | — | EP | disclosed |
| US-4889954-A | DIALKYLCARBONATE CATALYST | ETHYL CORPORATION (US) | 1989-12-26 | — | — | US | disclosed |
| EP-0307184-A2 | Preparation of Amine Oxides | ETHYL CORPORATION (US) | 1989-03-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12491185-B2 | Inhibitors of mPTP | PARK7, PINK1, SNCA | SIGMAR1 680/4885TAAR1 728/4885SLC6A2 45/4885 |
| US-20250177397-A1 | INHIBITORS OF MPTP | PARK7, PINK1, SNCA | SIGMAR1 680/4885TAAR1 728/4885SLC6A2 45/4885 |
| US-20260007672-A1 | INHIBITORS OF MPTP | PARK7, SNCA, CYC1 | SIGMAR1 60/4885TAAR1 195/4885SLC6A2 85/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.